Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men
- PMID: 1997637
- DOI: 10.1111/j.1365-2796.1991.tb00319.x
Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men
Abstract
The aim of this study was to evaluate the effect of treatment with subcutaneous injections of recombinant human erythropoietin (rhEpo), 20-40 IU kg-1 body weight, 3 times a week, on resting blood pressure, blood pressure response during submaximal exercise, some haematological parameters, and subjective side-effects in 15 healthy male subjects. RhEpo increased both haemoglobin (Hb) concentration and haematocrit (Hct) significantly, the values for Hb being 152 +/- 4.2 g l-1 before treatment and 169 +/- 9.3 g l-1 (mean values +/- SD) after 6 weeks of rhEpo treatment (P less than 0.001). The corresponding values for Hct were 44.5 +/- 1.5% and 49.7 +/- 1.9% (P less than 0.001), respectively. The systolic and diastolic blood pressure values at rest were unchanged after rhEpo treatment. A marked increase in systolic blood pressure was observed during submaximal exercise at 200 W, the initial and final values being 177 +/- 14.2 mmHg and 191 +/- 19.5 mmHg (P less than 0.01), respectively. Heart rate during exercise at 200 W was significantly lower after rhEpo treatment than before it: 144 +/- 15 beats min-1 compared to 136 +/- 8 beats min-1 (P less than 0.001). The leucocyte count remained unchanged after rhEpo treatment, but there was a significant decrease (P less than 0.05) in the number of lymphocytes. Reticulocyte and platelet counts were unchanged. Serum (S) ferritin decreased from 87.3 +/- 41.8 mmol l-1 to 59.3 +/- 27.8 mmol l-1 after rhEpo treatment (P less than 0.001). Serum-Na, S-K, S-Ca, S-creatinine, S-bilirubin, S-aspartate aminotransferase (ASAT), S-alanine aminotransferase (ALAT), and S-lactate dehydrogenase (LD) were unchanged after rhEpo treatment. No subjective side-effects were reported. In conclusion, low doses of rhEpo increased Hb levels and Hct by more than 10% after 6 weeks. Blood pressure at rest was unchanged, but rhEpo induced a markedly accentuated blood pressure reaction during exercise. A minor decrease in the lymphocyte count was observed, but electrolyte and creatinine levels remained unchanged after rhEpo treatment.
Similar articles
-
Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers.Br J Haematol. 1996 Feb;92(2):295-301. doi: 10.1046/j.1365-2141.1996.d01-1501.x. Br J Haematol. 1996. PMID: 8602988 Clinical Trial.
-
Influence of recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics during exercise in humans.J Physiol. 2005 Oct 15;568(Pt 2):639-52. doi: 10.1113/jphysiol.2005.089920. Epub 2005 Aug 4. J Physiol. 2005. PMID: 16081477 Free PMC article. Clinical Trial.
-
Effects of erythropoietin on erythrocyte deformability in non-transfused preterm infants.Acta Paediatr. 2007 Feb;96(2):253-6. doi: 10.1111/j.1651-2227.2007.00101.x. Acta Paediatr. 2007. PMID: 17429915 Clinical Trial.
-
Blood boosting and sport.Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Mar;14(1):89-98. doi: 10.1053/beem.2000.0056. Baillieres Best Pract Res Clin Endocrinol Metab. 2000. PMID: 10932813 Review.
-
Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid.Sports Med. 2002;32(2):125-42. doi: 10.2165/00007256-200232020-00004. Sports Med. 2002. PMID: 11817997 Review.
Cited by
-
Autologous Doping with Cryopreserved Red Blood Cells - Effects on Physical Performance and Detection by Multivariate Statistics.PLoS One. 2016 Jun 10;11(6):e0156157. doi: 10.1371/journal.pone.0156157. eCollection 2016. PLoS One. 2016. PMID: 27284981 Free PMC article. Clinical Trial.
-
Comparison of a direct and indirect population pharmacodynamic model: application to recombinant human erythropoietin in athletes.J Pharmacokinet Biopharm. 1997 Jun;25(3):263-75. doi: 10.1023/a:1025737024403. J Pharmacokinet Biopharm. 1997. PMID: 9474529
-
Exercise Testing, Physical Training and Fatigue in Patients with Mitochondrial Myopathy Related to mtDNA Mutations.J Clin Med. 2021 Apr 20;10(8):1796. doi: 10.3390/jcm10081796. J Clin Med. 2021. PMID: 33924201 Free PMC article. Review.
-
Exercise aggravates cardiovascular risks and mortality in rats with disrupted nitric oxide pathway and treated with recombinant human erythropoietin.Eur J Appl Physiol. 2011 Aug;111(8):1929-38. doi: 10.1007/s00421-011-1829-z. Epub 2011 Jan 20. Eur J Appl Physiol. 2011. PMID: 21249387
-
Genetic doping and health damages.Iran J Public Health. 2011;40(1):1-14. Epub 2011 Mar 31. Iran J Public Health. 2011. PMID: 23113049 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous